A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tolebrutinib (SAR442168) in Adults With Generalized Myasthenia Gravis (MG)
Latest Information Update: 11 Apr 2024
At a glance
- Drugs Tolebrutinib (Primary)
- Indications Myasthenia gravis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms URSA
- Sponsors Sanofi
- 08 Mar 2024 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
- 29 Apr 2023 This trial has been completed in Poland (End Date: 21 Feb 2023), according to the European Clinical Trials Database record.
- 10 Mar 2023 This trial has been completed in Hungary (End Date: 21 Feb 2023, according to the European Clinical Trials Database record.